Aurobindo Pharma stock falls 5% on USFDA, Zentiva talks

What moved the stock

Aurobindo Pharma’s share price saw sharp swings across multiple sessions as investors reacted to two separate sets of headlines: a potential overseas acquisition and regulatory observations at a domestic manufacturing unit. On Wednesday, August 20, 2025, the stock slipped almost 5% to ₹1,039 per share after reports suggested the company had emerged as a frontrunner to acquire Prague-based generic drugmaker Zentiva. In another instance, the stock fell nearly 5% intraday to ₹1,129.2 per share on a Wednesday after reports said the US Food and Drug Administration (USFDA) issued several observations at one of its units.

The market reaction underlined how quickly sentiment can shift for pharmaceutical manufacturers, where deal funding and regulatory compliance can change risk perceptions even without an immediate earnings downgrade. Stock exchanges also sought clarification from the company after the reports triggered a sharp decline.

Zentiva acquisition reports and the market’s initial reaction

Reports pegged the proposed Zentiva transaction at $1–5.5 billion, which was also cited as about ₹43,500–47,900 crore. If completed, it was described as the largest-ever acquisition by an Indian pharmaceutical company, across both domestic and overseas markets. The size of the deal became the key talking point, with investors weighing the potential strategic upside against the funding, leverage, and integration risks that large cross-border transactions typically involve.

On August 20, 2025, the stock’s near 5% fall to ₹1,039 reflected that caution. The move was tied directly to the acquisition narrative, rather than to any contemporaneous earnings shock. The key issue for markets was not just the headline value, but the uncertainty around whether the discussions would translate into a binding commitment.

What Aurobindo Pharma said on Zentiva

Following the reports, the company issued a clarification that sought to cool speculation. It said it regularly explores strategic opportunities, including acquisitions and partnerships. But it also stated that no binding agreement or board approval had been finalised regarding the Zentiva acquisition.

The company also called the news reports premature and said they should not be relied upon. That clarification mattered because it pushed the story back from “deal certainty” to “exploration,” which changes how investors model the possible financial impact.

USFDA observations at Telangana Unit 7: what was reported

In a separate development reported by CNBC-TV18, Aurobindo Pharma’s shares plunged in trade on February 18 amid reports of nine significant USFDA observations at its Unit 7 manufacturing facility in Telangana. Sanitation and contamination were described as key focus areas. The report said the regulator found equipment had not been cleaned for years, with references to E. coli and bird droppings in systems.

The same set of reports also cited data integrity and documentation concerns, including staff having deletion access of raw data, unexplained trial runs, backdating of microbiology documents, and mismatches between electronic dissolution data and physical records. Separately reported were issues such as inadequate controls over computer systems and processes, gaps in master manufacturing records, deficiencies in complaint handling and investigation records, and laboratory control mechanisms not being adhered to. One report also said it was observed that a microbiologist responsible for sample collection had falsified sample collection data.

How the stock traded during the USFDA headline cycle

After USFDA-related reports, Aurobindo Pharma shares fell as much as 4.85% to ₹1,129.2 per share, described as the biggest intraday fall since February 10 of that year. The stock later pared losses to trade 4.2% lower at ₹1,136.5 as of 11:10 AM, compared with a 0.08% decline in the Nifty 50 at the time.

In another session described in the provided data, the stock hit an over three-month low of ₹1,110.55, falling 8% intraday on the BSE after the company announced December 2025 quarter (Q3FY26) results on Monday after market hours. The stock closed at ₹1,144, down 5.31% for the day, underperforming its sector by nearly 5% and the Sensex by 5.52%.

Derivatives and technical signals flagged by the market

Derivatives activity was also highlighted, with a summary noting a near 20% jump in open interest alongside a 5.31% decline in the underlying stock price. The combination of rising open interest and falling price was framed as consistent with fresh short positions being built or existing shorts being increased.

Technical commentary in the provided data also said the stock was trading below key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day) at one point, indicating a bearish setup in the short to medium term. Delivery volume on 9 February was cited at 3.98 lakh shares, down 39.02% from the five-day average.

Operational incident: fire at APL Healthcare Unit-IV

Separately, Aurobindo Pharma reported a fire incident on September 18, 2025 at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit. The company said the fire was contained, with no casualties, and that it impacted two out of nineteen lines. The incident was estimated to reduce monthly capacity by about 3%, with refurbishment underway and operations expected to resume in a few weeks.

Key numbers at a glance

Market impact: what investors are reacting to

The common thread across these episodes is risk perception. A potential multi-billion-dollar acquisition can raise questions on funding structure and execution even before a binding agreement is signed. And USFDA observations, when reported as involving sanitation, contamination, and data integrity controls, can heighten concern because the US remains a critical market for Indian pharmaceutical exports.

The provided data also pointed to additional near-term drivers for price weakness, including broader market softness in NIFTYMIDCAP150, short-term profit booking after recent gains, and a more cautious stance on regulatory and operational updates within the sector. In parallel, a separate market-wide news item noted that Indian stocks extended losses for a sixth straight session on a Friday amid a sell-off in pharma stocks after US President Donald Trump announced fresh tariffs, including a 100% levy on branded drugs.

Analysis: why this matters for Aurobindo Pharma

For Aurobindo Pharma, the Zentiva story and the USFDA headlines represent two different kinds of uncertainty that can weigh on valuations at the same time. One relates to capital allocation and strategic direction, where the immediate market question is whether the company will pursue a transaction of the size reported, and on what terms. The other relates to compliance and operational controls, where the key question is how quickly issues can be addressed and how regulators respond.

The technical and derivatives signals mentioned in the provided data suggest traders were positioning defensively during some of these declines. A rising open interest alongside falling prices is often interpreted as bearish positioning, and falling delivery volumes can point to lower conviction among longer-term participants during a period of volatility.

Conclusion

Aurobindo Pharma’s stock declines were linked to two headline risks: reports of a $1–5.5 billion Zentiva acquisition and reports of nine USFDA observations at a Telangana facility. The company clarified that Zentiva-related reports were premature, with no binding agreement or board approval in place. Investors will likely continue to track any further exchange filings or regulatory updates, along with the company’s progress on restoring operations after the September 2025 fire incident.